Year : 2015 | Volume
: 8 | Issue : 4 | Page : 474--478
Cardiovascular effects of prolonged milrinone inhalation in patients with pulmonary hypertension undergoing mitral valve replacement
Sherif S Sultan, Khaled M.A. Abdelsalam
Department of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Inhaled milrinone has short-acting selective pulmonary vasodilator effect.
The aim of the study was to investigate the cardiovascular effects of prolonged inhalation of nebulized milrinone on patients with pulmonary hypertension undergoing mitral valve replacement.
Settings and design
This is a controlled, randomized, double-blinded study.
Patients and methods
Forty patients were divided into two groups: the milrinone group and the control group. The milrinone group received milrinone nebulization before cardiopulmonary bypass (CPB) as the loading dose at 50 mg/kg, followed by a maintenance dose of 0.5 mg/kg/min, which was continued for 2 h after tracheal extubation. The control group received an equivalent volume of 0.9% sodium chloride. The measured and calculated variables included heart rate, mean arterial blood pressure, central venous pressure, mean pulmonary artery pressure (mPAP), pulmonary capillary wedge pressure, cardiac index (CI), pulmonary vascular resistance (PVR), and systemic vascular resistance. The time points of measurements and calculations were as follows: at T 0 - after anesthesia induction and before sternotomy; at T 1 - 20 min after CPB cessation; at T 2 - 1 h after CPB cessation; at T 3 - 3 h after CPB cessation; at T 4 - 1 h after tracheal extubation; and at T 5 - 1 h after milrinone discontinuation. The duration of CPB and time of tracheal extubation were recorded.
The milrinone group showed significant reduction in mPAP (T 2 to T 4 readings), pulmonary capillary wedge pressure (T 3 reading), and PVR (T 2 to T 4 readings), increase in CI (T 3 and T 4 readings), and shorter CPB duration and tracheal extubation time.
Prolonged inhalation of nebulized milrinone proved to be feasible in patients with pulmonary hypertension (PAH) undergoing mitral valve replacement. It decreased PVR and mPAP while increasing CI. This helped shorter CPB duration and earlier tracheal extubation.
Sherif S Sultan
24 Muhammad Al-Maqreef St, Nasr City, Cairo 11762
|How to cite this article:|
Sultan SS, Abdelsalam KM. Cardiovascular effects of prolonged milrinone inhalation in patients with pulmonary hypertension undergoing mitral valve replacement.Ain-Shams J Anaesthesiol 2015;8:474-478
|How to cite this URL:|
Sultan SS, Abdelsalam KM. Cardiovascular effects of prolonged milrinone inhalation in patients with pulmonary hypertension undergoing mitral valve replacement. Ain-Shams J Anaesthesiol [serial online] 2015 [cited 2021 Oct 19 ];8:474-478
Available from: http://www.asja.eg.net/article.asp?issn=1687-7934;year=2015;volume=8;issue=4;spage=474;epage=478;aulast=Sultan;type=0